ClinicalTrials.gg
RecruitingNCT06795529TARGET-PCUpdated Nov 18, 2025

Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

An interventional study of Palliative Care Intervention, "TARGET-PC" and Enhanced Usual Care in Metastatic Breast Cancer, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Breast Neoplasms by Massachusetts General Hospital — 12 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Massachusetts General Hospital.

Planned enrollment
5th of 53
400 · median 51
Started
2025
the only one that year
No phase
33 of 66
8 open now
Primary completion
2029-10
later than 21 of 22 live
Registered
62nd of 66
by date

Among the 66 studies in Breast Neoplasms by Massachusetts General Hospital, this one is the 5th largest by planned enrollment of the 53 interventional ones that give a count, is the only one that started in 2025, is one of 33 with no phase, reaches primary completion later than 21 of the 22 other live ones, and was the 62nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 66 studies in Breast Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Breast Neoplasms by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not always happen as early or as often as patients and families would like. This multi-site study will test the effectiveness of a five-session palliative care program, designed specifically for people with metastatic breast cancer and their caregivers, to strengthen communication with clinicians about what matters most in their care. The study aims to inform how palliative care services can be delivered in a more timely, personalized, and scalable way for people living with advanced cancers who have long disease trajectories, such as metastatic breast cancer.

Read the detailed description

The diagnosis of metastatic breast cancer can bring many challenges including physical symptoms, treatment side effects, and emotional stress for patients and their families. Palliative care specialists work alongside the oncology team to help patients and families manage symptoms, communicate effectively with their clinicians, and cope with the impact of living with cancer.

Research has shown that when palliative care and oncology teams collaborate closely, patients often experience better symptom relief, clearer communication about their goals and preferences, improved quality of life and mood, and a stronger understanding of their illness. Caregivers also report feeling more supported and less distressed.

The purpose of this research study is to learn whether a personalized palliative care program for people with metastatic breast cancer and their caregivers, called TARGET-PC, can further improve communication, symptom management, coping skills, and understanding of care.

In this study, 400 patients with metastatic breast cancer and their caregivers will be randomly assigned to receive either the TARGET-PC program or enhanced usual care. Enhanced usual care includes an electronic prompt that reminds oncology clinicians to discuss and record each patient's goals and preferences for care. The study will take place at the Massachusetts General Hospital Cancer Center, Penn Abramson Cancer Center, and Duke Cancer Center.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • palliative care
  • communication about care preferences
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria:

  • age ≥18 years
  • diagnosed with breast cancer
  • within 8 weeks of the oncology visit at which they were identified as having an eligible Epic EOL Care Index (≥ 15)
  • functioning independently per an performance status ≤2
  • receiving their cancer care at one of the participating institutions
  • able to complete questionnaires in English or Spanish

Patient Exclusion Criteria:

  • received outpatient palliative care visit within the last six months
  • enrolled in hospice services
  • diagnosed with a comorbid condition that impairs their ability to understand study procedures and/or consent for the trial as per the report of the oncology clinician(s)

Caregiver Inclusion Criteria:

  • age ≥18 years
  • identified by the patient as a family member or friend who is primarily involved in their care
  • able to complete questionnaires in English or Spanish
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Palliative Care Intervention, "TARGET-PC"

    Patients randomly assigned to TARGET-PC will receive the palliative care intervention in addition to usual oncology care. Palliative care intervention visits will be conducted by a palliative care physician or advanced practice provider either in-person or with hospital-approved videoconference technology. Patients will be scheduled for their first palliative care visit within four weeks of randomization. Subsequent palliative care intervention visits will be scheduled every four weeks until the patient completes visit five. If a patient cannot be scheduled for intervention visits within four weeks, the palliative care clinician will contact them via telephone within four weeks of their prior contact to maintain their relationship and rapport. Palliative care clinicians will be permitted to conduct an intervention visit over the phone or video if they feel it is appropriate based on the patient's health status.

    Other: Palliative Care Intervention, "TARGET-PC"

  • Active comparator
    Enhanced Usual Care

    The oncology clinicians (physicians and advanced practice providers) of patients randomly assigned to the enhanced usual care condition will receive electronic prompts, encouraging them to discuss and document their patient's care preferences for up to five months after the patient is randomized. The prompts will be sent electronically. The research assistant will send the first electronic prompt on the morning of the outpatient oncology appointment immediately following the visit at which the patient provided informed consent for the study. Subsequent electronic prompts will be sent on the morning of outpatient oncology appointments for five months, but no more often than every four weeks.

    Other: Enhanced Usual Care

Interventions

  • OtherPalliative Care Intervention, "TARGET-PC"

    Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.

  • OtherEnhanced Usual Care

    Oncology clinicians will receive an electronic message to encourage them to discuss and document their patients' health care preferences.

06

What researchers measure

Primary outcomes

  1. Documentation of End-of-Life Care Preferences

    To compare proportions of patients with clinician-documented end-of-life care preferences in the electronic health record by last follow-up time point or date of death between study groups.

    Time frame: From date of randomization until date of death or last follow up assessed up to 60 months

Secondary outcomes

  1. Hospice Utilization

    To compare proportions of patients using hospice services by last follow up time point or death of death between study groups.

    Time frame: From date of randomization until date of death or last follow up assessed up to 60 months

  2. Hospice Length of Stay

    To compare patients' lengths of stay in hospice between study groups among patients who die during study follow up.

    Time frame: From date of randomization until date of death or last follow up assessed up to 60 months

  3. Death in the Hospital

    To compare proportions of patients dying in the hospital between study groups among patients who die during study follow up.

    Time frame: From date of randomization until date of death or last follow up assessed up to 60 months

  4. Patient-reported Communication about End-of-Life Care Preferences

    To compare proportions with patient-reported communication about their end-of-life care preferences between study groups by last follow-up time point or date of death using the Prognosis and Treatment Perceptions Questionnaire (PTPQ). The PTPQ has a single item in which patients indicate whether they have discussed their end-of-life care wishes with their clinicians (scored dichotomously as "yes or no").

    Time frame: From date of randomization until date of death or last follow up assessed up to 60 months

Other outcomes

  1. Patient Quality of Life (Functional Assessment of Cancer Therapy-Breast Scale)

    To compare patient-reported quality of life per the Functional Assessment of Cancer Therapy-Breast (FACT-B) Scale between study groups at 24 weeks. The FACT-B total scale scores range from 0-148, with higher scores indicating better quality of life.

    Time frame: 24 Weeks

  2. Patient Psychological Distress (Hospital Anxiety and Depression Scale - HADS)

    To compare patient-reported anxiety and depression symptoms per the Hospital Anxiety and Depression Scale (HADS) between study groups at 24 weeks. HADS subscale scores range from 0-21, with higher scores indicating worse distress.

    Time frame: 24 weeks

  3. Patient Coping (Brief COPE)

    To compare patient-reported use of approach-oriented and avoidant coping strategies per the Brief-COPE between study groups at 24 weeks. The Brief-COPE approach-oriented subscale scores range from 6-24, and the avoidant subscale scores range from 4-16, with higher scores indicating greater use of each strategy.

    Time frame: 24 weeks

  4. Caregiver Quality of Life (Caregiver Oncology QOL Questionnaire)

    To compare caregiver-reported quality of life per the Caregiver Oncology Quality-of-Life Questionnaire (CarGOQoL) between study groups at 24 weeks. The CarGOQoL total scale scores range from 0-100, with higher scores indicating better quality of life.

    Time frame: 24 Weeks

  5. Caregiver Psychological Distress (Hospital Anxiety and Depression Scale - HADS)

    To compare caregiver-reported anxiety and depression symptoms per the Hospital Anxiety and Depression Scale (HADS) between study groups at 24 weeks. HADS subscale scores range from 0-21, with higher scores indicating worse distress.

    Time frame: 24 weeks

  6. Caregiver Coping (Brief COPE)

    To compare caregiver-reported use of approach-oriented and avoidant coping strategies per the Brief-COPE between study groups at 24 weeks. The Brief-COPE approach-oriented subscale scores range from 6-24, and the avoidant subscale scores range from 4-16, with higher scores indicating greater use of each strategy.

    Time frame: 24 weeks

  7. Caregiver-reported Communication about the Patient's End-of-Life Care Preferences

    To compare caregiver-reported communication about the patient's end-of-life care preferences between study groups by last follow-up time point or the patient's date of death using the Prognosis and Treatment Perceptions Questionnaire (PTPQ). The PTPQ has a single item in which caregivers indicate whether they have discussed the patient's end-of-life care wishes with their clinicians (scored dichotomously as "yes or no").

    Time frame: From date of randomization until date of death or last follow up assessed up to 60 months

  8. Caregiver After Death Assessment

    To compare caregiver-reported assessment of the patient's end-of-life experiences between study groups among caregivers of patients who die during the study period as measured by three items ranging from 0-10, with higher scores indicating worse quality of end-of-life.

    Time frame: From date of randomization until three months after the patient's death assessed up to 60 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Greer JA, Moy B, El-Jawahri A, Jackson VA, Kamdar M, Jacobsen J, Lindvall C, Shin JA, Rinaldi S, Carlson HA, Sousa A, Gallagher ER, Li Z, Moran S, Ruddy M, Anand MV, Carp JE, Temel JS. Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer. J Natl Compr Canc Netw. 2022 Feb;20(2):136-143. doi: 10.6004/jnccn.2021.7040. PubMed 35130492 ↗

Individual participant data

Plan to share: Yes — The total scale, subscale scores, and item-level scores from the self-report measures, sociodemographic information, electronic health record data, and palliative care visit surveys will be preserved and stored within a secure computing environment. All participant identifiers will be removed and maintained in a separate secure file that will not be shared to protect confidentiality.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be submitted to a publicly available database within three months of study completion and maintained in perpetuity.

Access criteria: Most of the scientific data generated in this study, including the self-report and electronic health record data, will be made publicly available through the Harvard Dataverse. However, certain sociodemographic information and any other variables that are considered Protected Health Information and potentially identifying the patient participants (e.g., dates of birth and death) will be restricted. Restricted data would only be made available to users who demonstrate a valid research need and meet conditions of use. In accordance with the data repository methods, we will require the completion of a data use agreement form that stipulates data sharing under IRB-approved protocols.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2029, 48 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 48 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2025
First posted
Jan 28, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Oct 1, 2029
CompletionEst.
Mar 31, 2030
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06795529
Responsible party
Jennifer Temel, MD (Co-Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jan 28, 2025
Start date
Oct 1, 2025
Primary completion
Oct 1, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Nov 18, 2025

Study contacts

Jennifer Temel, MD
Contact
jtemel@mgh.harvard.edu
617-724-4000
Joseph Greer, PhD
Contact
jgreer2@mgh.harvard.edu
617-724-4000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion